Document Library
Filter by country
Africa
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
South-East Asia
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Filter by type
Country
Africa
South-East Asia
Americas
Europe
Western Pacific
Eastern Mediterranean
Documents
Annual Reports
AMC Documents
Country Documents
Evaluations
Financial Reports
Guidelines and Forms
Legal
Strategy
Supply and Procurement
Policies
White papers
Gavi Fact Sheets
Gavi Publications
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
Committee minutes
Audit
Spanish
Russian
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
Gavi Process Guidelines
Gavi Programme Funding Guidelines
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
VIS
News
AMC Updates
Gavi Features
Press Releases
Roi
Statements
Gavi Blogs
Vaccineswork
Theme - Pentavalent
Top stories
3rd donor pledging
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Audio Visual
Infographics
Presentations
Videos
Galleries
Market shaping
Phase I - innovations
Phase II - innovations
VIPS
Gender
Board
Committee
Members
Donor
Japan
Governments EU
Foundations corps orgs
RFP
Country managed evaluations
Old RFP
Centralised evaluations (EAC)
3rd donor pledging announcements
Types of support
Human papillomavirus
Inactivated polio vaccine
Japanese encephalitis
Measles and measles-rubella
Meningitis A
Oral cholera
Pentavalent
Pneumococcal
Rotavirus
Typhoid
Yellow fever
Health system strengthening
Hexavalent
DTP-containing booster
Board meetings
COVAX roll-out
Africa COVAX roll-out
Americas COVAX roll-out
Eastern Mediterranean COVAX roll-out
Europe COVAX roll-out
SE Asia COVAX roll-out
Western Pacific COVAX roll-out
Decentralised Evaluations
Decentralised Evaluations pages
Knowledge Products
Discussion Paper
Annual Evaluation Reports
Other learning products
CSO
CSO news
CSO story
CSO learning brief
Africa
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
South-East Asia
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Annual Reports
AMC Documents
Manufacturers related
Strategic Demand Forecast
Target Product Profile
Legal Agreements
Remaining offer amount
Country Documents
Approved proposals
Comprehensive multi-year plans, Financial sustainability plans, National Immunisation Strategy
Country co-financing information sheet
Data quality audit
Decision Letters and Partnerships Agreement
The joint appraisal report and Multi-Stakeholder Dialogue
Targeted country assistance plans
HSS evaluation
HSS tracking study
Annual progress reports
COVAX Technical Assistance Plans
Evaluations
CSO 2012
Full country evaluations
Second evaluation
IFFIm evaluation
HSS evaluation
TCA
Other studies
CSO 2018
Financial Reports
Guidelines and Forms
General
Japanese encephalitis vaccine
Meningitis A vaccine
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
HSS support
CCEOP support
Report on and renew support
TCA
Additional guidance
Joint appraisals
Tools and templates
Legal
Strategy
Phase 4
Phase 5
Phase 3
Phase 2
Phase 1
Risk
Supply and Procurement
Roadmaps
Base demand forecast
Detailed product profiles
Strategy 2016-20
Policies
Corporate
Programmatic
White papers
Gavi Fact Sheets
Gavi Publications
Japanese
Gavi progress reports
Arabic
Investment opportunity
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Decisions
Programme
2020
2021
2022
2023
2024
2025
2026
Committee minutes
PPC
EAC
IC
AFC
GC
Audit
Spanish
Russian
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
COVAX AMC VR
COVAX AMC TA
COVAX AMC CCE
COVAX AMC CDS (EA)
COVAX AMC CDS (NB)
Legal 1
Legal 2
Gavi Process Guidelines
Human papillomavirus vaccine
Measles and measles-rubella vaccines
Application Process
Application Kit
Analysis
Vaccine Information & Switches
Ongoing Portfolio Management, Reporting & Renewals
Financial Management & Reporting
Joint-Appraisal & Multi Stakeholder Dialogue
IPV
Meningococcal vaccines
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
Malaria vaccine
Cholera vaccine (OCV)
Gavi process guidelines 5.0
Vaccine switch information
Hexavalent guidelines
Ebola
Human rabies vaccine for post-exposure prophylasis
DTP guidelines
Gavi process guidelines 6.0
Gavi Programme Funding Guidelines
Zero-dose
Maintain, Restore & Strengthen
Demand, Communities and Gender
Supply Chain & Cold Chain Equipment
Data
Leadership, Management and Coordination
Immunisation Financing
Gavi Programme Funding Guidelines – Main
Additional Resources
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
Case studies & technical briefs
Practical guides
Digital Health Information Strategy
Research publications
VIS
VIS 2018
AMC Updates
Gavi Features
Press Releases
COVAX latest
Gavi partner
Roi
Statements
Gavi Blogs
Vaccineswork
Primary health care
Universal health care
Equity
Gender
Outbreaks
Technology and innovation
Antimicrobial resistance
Climate change
Urbanisation
Identity
Opinions
Country stories
COVID-19
Most read
Review
Partner
Featured VW articles
Featured Large VW article
MTR
Theme - Pentavalent
Top stories
HEHR
3rd donor pledging
Alliance partners
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
Manufacturers related
Strategic Demand Forecast
Target Product Profile
Legal Agreements
Remaining offer amount
Approved proposals
Approved proposals
Comprehensive multi-year plans, Financial sustainability plans, National Immunisation Strategy
Comprehensive multi-year plans, Financial sustainability plans, National Immunisation Strategy
Country co-financing information sheet
Country co-financing information sheet
Data quality audit
Data quality audit
Decision Letters and Partnerships Agreement
Decision Letters and Partnerships Agreement
The joint appraisal report and Multi-Stakeholder Dialogue
The joint appraisal report and Multi-Stakeholder Dialogue
Targeted country assistance plans
Targeted country assistance plans
HSS evaluation
HSS evaluation
HSS tracking study
HSS tracking study
Annual progress reports
Annual progress reports
COVAX Technical Assistance Plans
COVAX Technical Assistance Plans
CSO 2012
Full country evaluations
FCE 2016
FCE 2015
FCE 2014
FCE 2013
Second evaluation
IFFIm evaluation
HSS evaluation
Gavi managed evaluations
Summaries
TCA
Other studies
CSO 2018
General
Japanese encephalitis vaccine
Meningitis A vaccine
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
HSS support
CCEOP support
Report on and renew support
Tools and templates
Additional info
TCA
Additional guidance
Financial management
Programming guidance
Requirements for implementation
Gender related barriers
Immunisation financing
Leadership management coordination
Improving data quality
Joint appraisals
Tools and templates
Phase 4
Phase 5
Phase 3
Phase 2
Phase 1
Risk
Roadmaps
Vaccine roadmap
CCE roadmap
Diagnostics roadmaps
Base demand forecast
Detailed product profiles
Strategy 2016-20
COVAX latest
Gavi partner
Corporate
Programmatic
Infographics
Presentations
Videos
Galleries
Japanese
Gavi progress reports
Arabic
Investment opportunity
Primary health care
Universal health care
Equity
Gender
Outbreaks
Technology and innovation
Antimicrobial resistance
Climate change
Urbanisation
Identity
Opinions
Seth Berkley
Ngozi Okonjo-Iweala
Anuradha Gupta
Sania Nishtar
Country stories
COVID-19
Explainer
Blog
Key news
COVAX
COVAX AMC articles
Most read
1 Trending
2 Trending
3 Trending
4 Trending
5 Trending
6 Trending
Review
Partner
Featured VW articles
Featured Large VW article
MTR
Phase I - innovations
Phase II - innovations
VIPS
Vaccine roadmap
CCE roadmap
Diagnostics roadmaps
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
2019
26 June
26 June Presentations
4 Dec
4 Dec presentations
2018
6 June
28 Nov OLD
6 June presentations
28 Nov presentations
28 Nov
28 Nov Pre-Board briefings
6 June pre-board briefings
28 Nov NEW
2017
14 June
7 July
29 Nov
14 June presentations
29 Nov presentations
29 Nov NEW
14 June Tech briefings
14 June NEW
2016
22 June
7 Dec
22 June presentations
7 Dec presentations
22 June Tech briefings
2015
10 June
2 Dec
10 June presentations
2 Dec presentations
2 Dec Tech briefings
10 June Tech briefings
2014
18 June
10 Dec
18 June presentations
10 Dec presentations
10 Dec Tech briefings
18 June Tech briefings
2013
11 June
21 Nov
11 June presentations
21 Nov presentations
2012
12 June
4 Dec
12 June presentations
4 Dec presentations
2011
7 July
16 Nov
7 July presentations
16 Nov presentations
2010
16 June
30 Nov
16 June presentations
30 Nov presentations
2009
Decisions
Programme
Governance
Investment
Audit
Evaluation
2020
19 March
11 May
24 June
24 June presentations
30 July
30 July Presentations
29 Sept
29 Sept Presentations
15-17 Dec
15-17 Dec Presentations
2021
22 March
22 March Presentations
23-24 June
23-24 June Presentations
28 Sept
28 Sept Presentations
30 Nov - 2 Dec
30 Nov - 2 Dec Presentations
Board Decision
2022
22-23 June
22-23 June Presentations
7-8 December
7-8 December Presentations
Board Decision
2023
Board Decision
26-27 June
26-27 June Presentations
6-7 December
6-7 December Presentations
2024
6-7 June
6-7 June Presentations
Board Decision
4-5 December
4-5 December Presentations
2025
24-25 July
24-25 July Presentations
Board Decision
3-4 December
3-4 December Presentations
2026
1-2 July
1-2 July Presentations
Board Decision
26 June
26 June Presentations
4 Dec
4 Dec presentations
6 June
28 Nov OLD
6 June presentations
28 Nov presentations
28 Nov
28 Nov Pre-Board briefings
6 June pre-board briefings
28 Nov NEW
14 June
7 July
29 Nov
14 June presentations
29 Nov presentations
29 Nov NEW
14 June Tech briefings
14 June NEW
22 June
7 Dec
22 June presentations
7 Dec presentations
22 June Tech briefings
10 June
2 Dec
10 June presentations
2 Dec presentations
2 Dec Tech briefings
10 June Tech briefings
18 June
10 Dec
18 June presentations
10 Dec presentations
10 Dec Tech briefings
18 June Tech briefings
11 June
21 Nov
11 June presentations
21 Nov presentations
12 June
4 Dec
12 June presentations
4 Dec presentations
7 July
16 Nov
7 July presentations
16 Nov presentations
16 June
30 Nov
16 June presentations
30 Nov presentations
PPC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
EAC
2009
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2020
2021
2022
2023
2024
2025
IC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2026
AFC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
GC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
2009
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2020
2021
2022
2023
2024
2025
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2026
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
Recommendation
2022
Recommendation
2023
Recommendation
2024
Recommendation
2025
2026
Recommendation
Seth Berkley
Ngozi Okonjo-Iweala
Anuradha Gupta
Sania Nishtar
Committee
Members
Japan
Governments EU
Foundations corps orgs
Tools and templates
Additional info
Financial management
Programming guidance
Requirements for implementation
Gender related barriers
Immunisation financing
Leadership management coordination
Improving data quality
Governance
Investment
Audit
Evaluation
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
FCE 2016
FCE 2015
FCE 2014
FCE 2013
Gavi managed evaluations
Summaries
HEHR
Alliance partners
Explainer
Blog
Key news
COVAX
COVAX key articles
COVAX AMC articles
Human papillomavirus
Inactivated polio vaccine
Japanese encephalitis
Measles and measles-rubella
Meningitis A
Oral cholera
Pentavalent
Pneumococcal
Rotavirus
Typhoid
Yellow fever
Health system strengthening
Hexavalent
DTP-containing booster
19 March
11 May
24 June
24 June presentations
30 July
30 July Presentations
29 Sept
29 Sept Presentations
15-17 Dec
15-17 Dec Presentations
1 Trending
2 Trending
3 Trending
4 Trending
5 Trending
6 Trending
COVAX key articles
COVAX AMC VR
COVAX AMC TA
COVAX AMC CCE
COVAX AMC CDS (EA)
COVAX AMC CDS (NB)
Legal 1
Legal 2
Africa COVAX roll-out
Americas COVAX roll-out
Eastern Mediterranean COVAX roll-out
Europe COVAX roll-out
SE Asia COVAX roll-out
Western Pacific COVAX roll-out
22 March
22 March Presentations
23-24 June
23-24 June Presentations
28 Sept
28 Sept Presentations
30 Nov - 2 Dec
30 Nov - 2 Dec Presentations
Board Decision
Recommendation
Human papillomavirus vaccine
Measles and measles-rubella vaccines
Application Process
Application Kit
FPP Application Guidelines & Materials
Standalone EAF Application Materials & Guidelines
Standalone Vaccine Application Materials & Guidelines
Standalone TCA Application Materials & Guidelines
Standalone CCEOP Application Materials & Guidelines
Standalone Innovation Top-up Application Materials & Guidelines
Gavi Middle Income Countries (MICs)
Analysis
Vaccine Information & Switches
Ongoing Portfolio Management, Reporting & Renewals
Financial Management & Reporting
Joint-Appraisal & Multi Stakeholder Dialogue
IPV
Meningococcal vaccines
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
Malaria vaccine
Cholera vaccine (OCV)
Gavi process guidelines 5.0
Vaccine switch information
Hexavalent guidelines
Ebola
Human rabies vaccine for post-exposure prophylasis
DTP guidelines
Gavi process guidelines 6.0
Gavi 6.0 application kit
FPP Application Guidelines & Materials
Standalone EAF Application Materials & Guidelines
Standalone Vaccine Application Materials & Guidelines
Standalone TCA Application Materials & Guidelines
Standalone CCEOP Application Materials & Guidelines
Standalone Innovation Top-up Application Materials & Guidelines
Gavi Middle Income Countries (MICs)
Zero-dose
Maintain, Restore & Strengthen
Demand, Communities and Gender
Supply Chain & Cold Chain Equipment
Data
Leadership, Management and Coordination
Immunisation Financing
Gavi Programme Funding Guidelines – Main
Additional Resources
Discussion Paper
22-23 June
22-23 June Presentations
7-8 December
7-8 December Presentations
Board Decision
Recommendation
Board Decision
26-27 June
26-27 June Presentations
6-7 December
6-7 December Presentations
Recommendation
Case studies & technical briefs
Practical guides
Digital Health Information Strategy
Research publications
VIS 2018
6-7 June
6-7 June Presentations
Board Decision
4-5 December
4-5 December Presentations
Recommendation
CSO news
CSO story
CSO learning brief
24-25 July
24-25 July Presentations
Board Decision
3-4 December
3-4 December Presentations
Gavi 6.0 application kit
1-2 July
1-2 July Presentations
Board Decision
Recommendation
09 Vaccine Budget Policy PPT pdf
gavi.org
09 –VACCINE BUDGET POLICY
BOARD MEETING
Johannes Ahrendts
1-2 July 2026, Geneva, Switzerland
One Vaccine Budget for the entire 6.0 Strategic period
Countryobtains vaccines
within a set budget amount
at the start of the strategic
period
From:
Country applied for as
many vaccine programmes
as needed (if they had
capacity & could co-
finance) at any time
To :
Vaccine budgets make planning and budgeting more predictable and help guide countries to prioritise
US$ million
Country X
Gavi 5.0/5.1 Country X
Gavi 6.0
2
Board approved design in December 2025. Now hardcoding decision into policy and adding approach for annual review and update of Vaccine Budgets.
Board Meeting, 1- 2 July 2026
09 –VACCINE BUDGET POLICY
BOARD MEETING
Johannes Ahrendts
1-2 July 2026, Geneva, Switzerland
One Vaccine Budget for the entire 6.0 Strategic period
Countryobtains vaccines
within a set budget amount
at the start of the strategic
period
From:
Country applied for as
many vaccine programmes
as needed (if they had
capacity & could co-
finance) at any time
To :
Vaccine budgets make planning and budgeting more predictable and help guide countries to prioritise
US$ million
Country X
Gavi 5.0/5.1 Country X
Gavi 6.0
2
Board approved design in December 2025. Now hardcoding decision into policy and adding approach for annual review and update of Vaccine Budgets.
Board Meeting, 1- 2 July 2026
10 Health Systems and Immunisation Strengthening Policy PPT pdf
gavi.org
10 –HEALTH SYSTEMS
AND IMMUNISATION
STRENGTHENING POLICY
BOARD MEETING
Ombline Richard
1 -2 July 2026, Geneva, Switzerland
Updating the Health Systems and Immunisation
Strengthening (HSIS) Policy to align with the Gavi Leap
and introduction of Vaccine Budgets
2 Gavi Board Meeting 1-2 July 2026
Focus of
policy
update
Approach to
allocation of
Vaccine
Implementation
Support Follow
-up on
open items
from July 2025
Board Approval A B
10 –HEALTH SYSTEMS
AND IMMUNISATION
STRENGTHENING POLICY
BOARD MEETING
Ombline Richard
1 -2 July 2026, Geneva, Switzerland
Updating the Health Systems and Immunisation
Strengthening (HSIS) Policy to align with the Gavi Leap
and introduction of Vaccine Budgets
2 Gavi Board Meeting 1-2 July 2026
Focus of
policy
update
Approach to
allocation of
Vaccine
Implementation
Support Follow
-up on
open items
from July 2025
Board Approval A B
11 Strategic Approach on Campaign Optimisation PPT pdf
gavi.org
11 –STRATEGIC APPROACH
ON CAMPAIGN OPTIMISATION
BOARD MEETING
Johannes Ahrendts,
Emanuele Capobianco
1 -2 July 2026, Geneva, Switzerland
Campaigns are essential to close immunity gaps, but
persistent challenges continue to limit their optimal use
2
Campaign monitoring tends to beweak, fragmented from routine immunisation and not
systematically used to inform corrective actions
Reliance on analogue systems for payments and campaign planning and implementation
contributes to implementation delays, loss and misuse of funds and security risks
Nationwide standalone campaigns are still predominant even where more efficient alternative
designs would be appropriate
Coordination among Alliance global, regional and country level partners needs improvements to
drive integrated campaign delivery strategies up to the last mile
Campaigns are often not integrated with other campaigns and withroutine immunisation
Countries have faced limited exposure to campaign vaccine costs
NON-EXHAUSTIVE, FOCUS ON CHALLENGES GAVI CAN ACT ON AMID FUNDING CONSTRAINTS
Board Meeting, 1- 2 July 2026
11 –STRATEGIC APPROACH
ON CAMPAIGN OPTIMISATION
BOARD MEETING
Johannes Ahrendts,
Emanuele Capobianco
1 -2 July 2026, Geneva, Switzerland
Campaigns are essential to close immunity gaps, but
persistent challenges continue to limit their optimal use
2
Campaign monitoring tends to beweak, fragmented from routine immunisation and not
systematically used to inform corrective actions
Reliance on analogue systems for payments and campaign planning and implementation
contributes to implementation delays, loss and misuse of funds and security risks
Nationwide standalone campaigns are still predominant even where more efficient alternative
designs would be appropriate
Coordination among Alliance global, regional and country level partners needs improvements to
drive integrated campaign delivery strategies up to the last mile
Campaigns are often not integrated with other campaigns and withroutine immunisation
Countries have faced limited exposure to campaign vaccine costs
NON-EXHAUSTIVE, FOCUS ON CHALLENGES GAVI CAN ACT ON AMID FUNDING CONSTRAINTS
Board Meeting, 1- 2 July 2026
12 Fragile and Humanitarian Approach PPT pdf
gavi.org
12 –FRAGILE AND
HUMANITARIAN APPROACH
BOARD MEETING
Alex de Jonquières , Alex Beecher
1 -2 July 2026, Geneva, Switzerland
Seven strategic shifts tailor Gavi’s delivery model to improve
effectiveness in Fragile & Humanitarian (F&H) settings
Strengthen and increase coverage with context-appropriate vaccines
Differentiate health systems support to missed communities and zero- dose children
aged 1- 5 years old
Institute new ways to direct vaccines and cash to missed communities
Support subnational settings and F&H settings in catalytic phase countries
Establish immunisation as a humanitarian health practice
Ensure a better equipped Gavi Secretariat
1
2
3
4
5
7
Create a dedicated ‘Gavi Resilience Mechanism’ 6
Board Meeting, 1- 2 July 2026 2
12 –FRAGILE AND
HUMANITARIAN APPROACH
BOARD MEETING
Alex de Jonquières , Alex Beecher
1 -2 July 2026, Geneva, Switzerland
Seven strategic shifts tailor Gavi’s delivery model to improve
effectiveness in Fragile & Humanitarian (F&H) settings
Strengthen and increase coverage with context-appropriate vaccines
Differentiate health systems support to missed communities and zero- dose children
aged 1- 5 years old
Institute new ways to direct vaccines and cash to missed communities
Support subnational settings and F&H settings in catalytic phase countries
Establish immunisation as a humanitarian health practice
Ensure a better equipped Gavi Secretariat
1
2
3
4
5
7
Create a dedicated ‘Gavi Resilience Mechanism’ 6
Board Meeting, 1- 2 July 2026 2
13 Ukraine Fragility Support PPT pdf
gavi.org
13 -UKRAINE FRAGILITY SUPPORT
BOARD MEETING
Thabani Maphosa
1-2 July 2026, Geneva, Switzerland
2 Board Meeting, 1-2 July 2026
2003
Gavi Support to Ukraine
HepB vaccine
6.9 million doses. US$ 3.5 million
Vaccine Introduction Grant (VIG)
CDS
US$ 9.4 million
C19 Programme 959,520 doses
(US$ 6.5 million)
C O VAX
13.2 million doses
US$ 99 million (vaccines +
Cold Chain Equipment -CCE)
MICs Fragility Support
US$ 8 million (US$ 6.5 million vaccine + US$ 1.5 million
Technical Assistance -TA
1)
Board Approved
GRM Fragility Support
US$ 5.8 million (US$ 4.9 million vaccine + US$ 888,000
Technical Assistance -TA )
2009 2021 2025 2024 2023 M AR
2026 JUN
2026
MICS NVI Support
US$ 950,000 HPV
Technical Assistance (TA)
Post Conflict Support 2022 - 2026
2022
1 – MICS TA grants end 30/06/2026
13 -UKRAINE FRAGILITY SUPPORT
BOARD MEETING
Thabani Maphosa
1-2 July 2026, Geneva, Switzerland
2 Board Meeting, 1-2 July 2026
2003
Gavi Support to Ukraine
HepB vaccine
6.9 million doses. US$ 3.5 million
Vaccine Introduction Grant (VIG)
CDS
US$ 9.4 million
C19 Programme 959,520 doses
(US$ 6.5 million)
C O VAX
13.2 million doses
US$ 99 million (vaccines +
Cold Chain Equipment -CCE)
MICs Fragility Support
US$ 8 million (US$ 6.5 million vaccine + US$ 1.5 million
Technical Assistance -TA
1)
Board Approved
GRM Fragility Support
US$ 5.8 million (US$ 4.9 million vaccine + US$ 888,000
Technical Assistance -TA )
2009 2021 2025 2024 2023 M AR
2026 JUN
2026
MICS NVI Support
US$ 950,000 HPV
Technical Assistance (TA)
Post Conflict Support 2022 - 2026
2022
1 – MICS TA grants end 30/06/2026
14 Gavi 60 Measurement Framework PPT pdf
gavi.org
14 -GAVI 6.0 MEASUREMENT FRAMEWORK
BOARD MEETING
Hope Johnson
1-2 July 2026, Geneva, Switzerland
•Programmatic ambition linked to anticipated expenditure
• Key assumptions will be regularly tracked to support interpretation
Targets for Gavi 6.0 measurement framework define topline ‘vision of
success’ for Gavi 6.0 strategic objectives with shared Alliance accountability
2
Proposed Gavi 6.0 measurement framework targets informed by Gavi financial forecast
(v23.1) and developed with Alliance Technical Working Group
•8-9 million future deaths averted consistent with Gavi 6.0 IO ,butmay be challenging without full
funding to replenishment ask; Recalibration and current funding context suggest likely to exceed 7.5 million
• 4-5 million additional zero -dose children reached reflecting country realities and funding levels; An
achievable target with distinct framing to avoid confusion with IA2030 target (PPC recommendation)
• A target of 50% of Gavi56 countries reaching IPVc coverage of at least 80% is proposed, with reporting
of disaggregated data on 13 high -risk polio countries (PPC recommendation)
Ambitious targets proposed for health impact and reaching zero -dose children
Supplemented by operationally focused indicators in the Gavi Leap Master Dashboard (GLMD)
•Gavi Leap Master Dashboard provides more timely information about progress on strategy
implementation , with accountabilities for secretariat, partners and countries and reported regularly to
the PPC and Board alongside the Gavi 6.0 measurement framework
Board Meeting, 1- 2 July 2026
14 -GAVI 6.0 MEASUREMENT FRAMEWORK
BOARD MEETING
Hope Johnson
1-2 July 2026, Geneva, Switzerland
•Programmatic ambition linked to anticipated expenditure
• Key assumptions will be regularly tracked to support interpretation
Targets for Gavi 6.0 measurement framework define topline ‘vision of
success’ for Gavi 6.0 strategic objectives with shared Alliance accountability
2
Proposed Gavi 6.0 measurement framework targets informed by Gavi financial forecast
(v23.1) and developed with Alliance Technical Working Group
•8-9 million future deaths averted consistent with Gavi 6.0 IO ,butmay be challenging without full
funding to replenishment ask; Recalibration and current funding context suggest likely to exceed 7.5 million
• 4-5 million additional zero -dose children reached reflecting country realities and funding levels; An
achievable target with distinct framing to avoid confusion with IA2030 target (PPC recommendation)
• A target of 50% of Gavi56 countries reaching IPVc coverage of at least 80% is proposed, with reporting
of disaggregated data on 13 high -risk polio countries (PPC recommendation)
Ambitious targets proposed for health impact and reaching zero -dose children
Supplemented by operationally focused indicators in the Gavi Leap Master Dashboard (GLMD)
•Gavi Leap Master Dashboard provides more timely information about progress on strategy
implementation , with accountabilities for secretariat, partners and countries and reported regularly to
the PPC and Board alongside the Gavi 6.0 measurement framework
Board Meeting, 1- 2 July 2026
01d Consent Agenda as at 29 June 2026 pdf
1
Board-2026-Mtg -02-Doc 01d
Report to the Board
1-2 July 2026
Subject Consent Agen da – as at 29 June 202 6
Agenda item 01 d
Category For Decision
Section A : Introduction
Three recommendations are being presented to the Board under the Consent Agenda
for consideration. Detailed information on the items can be found in the relevant
Committee papers in a dedicated folder on BoardEffect at:
https://gavi.boardeffect -
uk.diligentoneplatform.com/workrooms/6459/library/files?folderId=325944
Section B : Actions Requested of the Board
The Gavi Alliance Board is requested to consider the following recommendations from
the Gavi Alliance Governance Committee and the Gavi Alliance Programme and
Policy Committee .
Decision One – IRC Chair and Investment Committee Chair appointment s
The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board
that it:
• Appoint Dr. Rana Hajjeh as Independent Review Committee (IRC) Chair for a
3 -year term, effective immediately.
• Appoint Henry Gonzalez, as an Unaffiliated Board Member, effective 1
November 2026 and until 31 October 2029.
• Appoint Henry Gonzalez , as Chair of the Investment Committee, effective 1
November 2026 and until 31 December 2027.
Decision Two – Board Vice Chair Appointment
The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board
that it:
• Appoint Mekdes Daba, as Vice Chair of the Board with individual signatory
authority, effective 1 October 2026 and until 30 September 2028.
• Appoint Mekdes Daba, as Chair of the Governance Committee, effective 1
October 2026 and until 31 December 2027.
Board-2026-Mtg -02-Doc 01d
Report to the Board
1-2 July 2026
Subject Consent Agen da – as at 29 June 202 6
Agenda item 01 d
Category For Decision
Section A : Introduction
Three recommendations are being presented to the Board under the Consent Agenda
for consideration. Detailed information on the items can be found in the relevant
Committee papers in a dedicated folder on BoardEffect at:
https://gavi.boardeffect -
uk.diligentoneplatform.com/workrooms/6459/library/files?folderId=325944
Section B : Actions Requested of the Board
The Gavi Alliance Board is requested to consider the following recommendations from
the Gavi Alliance Governance Committee and the Gavi Alliance Programme and
Policy Committee .
Decision One – IRC Chair and Investment Committee Chair appointment s
The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board
that it:
• Appoint Dr. Rana Hajjeh as Independent Review Committee (IRC) Chair for a
3 -year term, effective immediately.
• Appoint Henry Gonzalez, as an Unaffiliated Board Member, effective 1
November 2026 and until 31 October 2029.
• Appoint Henry Gonzalez , as Chair of the Investment Committee, effective 1
November 2026 and until 31 December 2027.
Decision Two – Board Vice Chair Appointment
The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board
that it:
• Appoint Mekdes Daba, as Vice Chair of the Board with individual signatory
authority, effective 1 October 2026 and until 30 September 2028.
• Appoint Mekdes Daba, as Chair of the Governance Committee, effective 1
October 2026 and until 31 December 2027.